Risk of estrogen-driven malignancies in females on 5-alpha reductase inhibitors
November 2024
in “
Archives of Dermatological Research
”
Research cited in this study
5 / 5 resultsresearch Female Pattern Hair Loss: Therapeutic Update
Topical minoxidil is the best-supported treatment for female hair loss, but personalized plans are needed.
research The Efficacy and Safety of Dutasteride Compared with Finasteride in Treating Men with Androgenetic Alopecia: A Systematic Review and Meta-Analysis
Dutasteride more effectively treats hair loss than finasteride, but may increase risk of altered libido.
research Safety of 5α-Reductase Inhibitors and Spironolactone in Breast Cancer Patients Receiving Endocrine Therapies
The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.
research 5-Alpha Reductase Inhibitors and Risk of Male Breast Cancer: A Systematic Review and Meta-Analysis
Taking 5-alpha reductase inhibitors does not increase the risk of breast cancer in men.
research The Effect of 5α-Reductase Inhibition with Dutasteride and Finasteride on Semen Parameters and Serum Hormones in Healthy Men
Dutasteride and finasteride may reduce sperm count and volume but don't affect movement or shape; effects are reversible after stopping.
Related Research
1 / 1 resultsresearch Establishment of Type II 5α-Reductase Over-Expressing Cell Line as an Inhibitor Screening Model
A reliable model for screening type II 5α-reductase inhibitors was created and validated.